1	State of Arkansas As Engrossed: HZ/24/25 HZ/26/25
2	95th General Assembly A Bill
3	Regular Session, 2025 HOUSE BILL 1442
4	
5	By: Representative Achor
6	By: Senators D. Wallace, C. Penzo
7	
8	For An Act To Be Entitled
9	AN ACT TO SET RESTRICTIONS ON PHARMACY CONTRACTING
10	AND CONFLICTS OF INTEREST; TO ESTABLISH
11	PHARMACEUTICAL PATIENT FREEDOM OF CHOICE; AND FOR
12	OTHER PURPOSES.
13	
14	
15	Subtitle
16	TO SET RESTRICTIONS ON PHARMACY
17	CONTRACTING AND CONFLICTS OF INTEREST;
18	AND TO ESTABLISH PHARMACEUTICAL PATIENT
19	FREEDOM OF CHOICE.
20	
21	BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
22	
23	SECTION 1. Arkansas Code Title 17, Chapter 92, Subchapter 4, is
24	amended to add an additional section to read as follows:
25	17-92-414. Prohibition of pharmacy contracting - Conflicts of interest
26	 Pharmacy permit holder responsibilities - Definition.
27	(a) It is the intent of the General Assembly to preserve patient
28	access, to improve quality of care outcomes, and to prevent anti-competitive
29	patient steering for pharmacy care services.
30	(b) As used in this section, "parent entity" means a federally
31	qualified health center, a Federally Qualified Health Center Look-Alike, or a
32	for-profit, nonprofit, tax-exempt, or governmentally funded hospital that has
33	a direct or indirect interest or ownership in a licensed pharmacy permit for
34	the sale at retail of drugs and medicines.
35	(c) A parent entity shall not:
36	(1) Financially incentivize a patient or plan beneficiary to

1 obtain a pharmacist's services from a pharmacy with terms that are not 2 offered equally at other network pharmacies; 3 (2)(A) Allow a pharmacy to be a limited provider of pharmacist's 4 services through the use of a network design that limits the number of 5 providers in said network. 6 (B) The Arkansas State Board of Pharmacy may exempt a 7 parent entity from subdivision (c)(2)(A) of this section on a per-pharmacy-8 contract basis if the parent entity demonstrates a verified net financial 9 loss for the proposed contract; or (3) Limit a patient's freedom of choice through financial 10 11 incentives. 12 (d) Upon receiving a complaint involving a violation of subsection (c) 13 of this section, the board shall investigate the complaint and schedule a hearing within thirty (30) business days of receipt of the complaint. 14 15 (e) A repetitive violation of this section is also a violation of the Unfair Practices Act, § 4-75-201 et seq. 16 17 (f) Market-based cash pricing of a drug or medication delinked from 18 any program assistance, contract, or network agreement of a drug or 19 medication is not a financial incentive under this section. 20 (g)(1) A parent entity that owns pharmacies and offers prospective cash savings plans through the 340B Drug Pricing Program shall allow other 21 22 network pharmacies to participate in the prospective cash savings plan. 23 (2) A parent entity is exempt from subdivision (g)(1) of this section on a per-pharmacy-contract basis if the board finds that the parent 24 25 entity demonstrates a violation of terms or conditions of the 340B Drug Pricing Program prospective cash savings plan by the contracted pharmacy. 26 27 (3) A parent entity is exempt from subdivision (g)(1) of this 28 section on a per-pharmacy contract basis if the prospective cash savings plan 29 offered through the 340B Drug Pricing Program is solely a cost recovery model 30 that does not include any dispensing or patient management fees and limits the amount charged to the patient not to exceed the 340B Drug Pricing Program 31 32 acquisition cost plus itemizable administration or processing fees. (h) A prospective cash savings plan offered through the 340B Drug 33 34 Pricing Program that is solely a cost recovery model that does not include 35 any dispensing or patient management fees and limits the amount charged to 36 the patient not to exceed the 340B Drug Pricing Program acquisition cost plus

1	itemizable administration or processing fees is not a financial incentive						
2	under this section.						
3	(i) A patient assistance program that utilizes or maximizes						
4	pharmaceutical manufacturer cost or payment assistance for patients who have						
5	opted in to participate in the patient assistance program is not a financial						
6	incentive under this section.						
7	(j) The board shall determine if there has been any violation of this						
8	section during the inspections conducted by the board.						
9	(k)(l) The board may issue temporary exemptions to this section on a						
10	per-permit-holder basis to specific limited distribution or specialty item						
11	drugs or to promote, preserve, and protect the public health, safety, and						
12	welfare through the effective regulation of the aspects of the drug delivery						
13	system.						
14	(2) The board may promulgate rules to implement subdivision						
15	(k)(1) of this section.						
16							
17	SECTION 2. Arkansas Code Title 23, Chapter 99, is amended to add an						
18	additional subchapter to read as follows:						
19	Subchapter 19 — Pharmaceutical Patient Freedom of Choice						
20							
21	23-99-1901. Legislative intent.						
22	It is the intent of the General Assembly to provide a right to freedom						
23	of choice in selecting prescriptions or pharmaceutical supplies and services						
24	from a pharmacy of the patient or responsible party.						
25							
26	23-99-1902. Definition.						
27	As used in this subchapter, "pharmacy treatment plan" means a plan of						
28	care for choice in preferred pharmacy, change of pharmacy, or choice of						
29	multiple pharmacies depending on a patient's health conditions, needs, and						
30	preferences.						
31							
32	23-99-1903. Pharmaceutical patient freedom of choice.						
33	(a) A patient or his or her responsible party shall have freedom of						
34	choice of pharmacy or pharmacy treatment plan by any permit holder of the						
35	Arkansas State Board of Pharmacy.						
36	(b) A patient may make a selection of pharmacy or pharmacy treatment						

1	plan only	when	the pa	tient	or	his	or	her	responsible	party	is	fully	informed
2	of his or	her i	freedom	of cl	noic	ce.							

- 3 (c) Any permit holder of the board shall not participate in any plan, 4 agreement, or arrangement that eliminates or detrimentally affects the
- traditional relationship of physician, patient, pharmacist, and the patient's freedom of choice of professional services.
- 7 (d)(1) If a for-profit, nonprofit, tax exempt, or governmentally
- 8 <u>funded hospital</u>, <u>federally qualified health center</u>, or a <u>Federally Qualified</u>
- 9 <u>Health Center Look-Alike that has direct or indirect interest in a permit</u>
- 10 holder of the board and a patient is receiving prescriptions issued by
- ll prescribers providing services in or for the hospital, emergency room, health
- 12 system clinic, or any other associated health system facilities for the
- 13 permit holder, the permit holder shall document the patient's choice of
- 14 pharmacy or pharmacy treatment plan.
- 15 (2) The permit holder under subdivision (d)(1) of this section
- 16 <u>shall maintain:</u>
- 17 (A) Documentation of the patient's choice of pharmacy or
- 18 pharmacy treatment plan in the patient's medical record, pharmacy management
- 19 system, or files; and
- 20 <u>(B) Policies and procedures that document how the</u>
- 21 patient's freedom of choice of pharmacy or pharmacy treatment plan is
- 22 maintained.
- 23 (e) A patient may choose or change the provider pharmacy at any time.
- 24 (f) The board may review documentation, policies, and procedures
- 25 <u>required under this section for the permit holders of the board during an</u>
- 26 <u>inspection by the</u> board.
- 27 (g) A patient assistance program that utilizes or maximizes
- 28 pharmaceutical manufacturer cost or payment assistance for patients who have
- 29 opted in to participate in the patient assistance program is not a violation
- 30 of patient freedom of choice under this section.
- 31 <u>(h)(1) The board may issue temporary exemptions to this section on a</u>
- 32 per-permit-holder basis to specific limited distribution or specialty item
- 33 drugs or to promote, preserve, and protect the public health, safety, and
- 34 welfare through the effective regulation of the aspects of the drug delivery
- 35 <u>system.</u>
- 36 <u>(2) The board may promulgate rules to implement subdivision</u>

1	(h)(l) of this section.	
2		/s/Achor
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		